Damora Therapeutics is expected to report zero revenue and a consensus EPS of -$0.38 for Q2 2026, with the current share price of $29.92 sitting significantly below the $44.00 average analyst target.
Investors are primarily focused on the regulatory timeline for lead candidate DMR-001, specifically the company's progress toward an Investigational New Drug (IND) application expected in mid-to-late 2026.
The company maintains a strong balance sheet with approximately $532.9 million in cash at the start of the quarter, providing a multi-year runway to fund its clinical pipeline targeting mutant calreticulin-driven hematologic disorders. This report serves as a pivotal update on cash burn efficiency and the company's competitive standing against rival therapies.